# special issue

# iwCLL 2023

# Table of Contents

- Preface S164
- Continuous BTK inhibition and combination regimens: present and future S167
- Long-term results and other findings from clinical trials S170
- Overcoming resistance to targeted inhibitors S174
- CLL treatment in the real world: insights from across the globe S176
- Issues in the management of CLL patients from an international point of view S177
- Interview: Different perspectives on how to define success in CLL

# Editorial Board:

Othman Al-Sawaf, MD, University of Cologne, Cologne, Germany

Jorge J. Castillo, MD, Dana-Farber Cancer Institute, Boston, USA

Shirley D’Sa, MD, FRCP, FRCPath, University College London Hospitals NHS Foundation Trust

Heinz Ludwig, MD, Wilhelminen Hospital, Vienna, Austria

Reid W. Merryman, MD, Boston, Dana Farber Cancer Institute, Boston, USA

Alison J. Moskowitz, MD, Memorial Sloan Kettering Cancer Center, New York, USA

Paolo G. Nuciforo, MD, PhD, Molecular Oncology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain

Constantine Tam, MD, Monash University, Melbourne, Australia

Andrea Visentin, MD, Universitá degli Studi di Padova, Padova, Italy

Stefan Vogt, MD, Lebens.Med Zentrum Bad Erlach, Department of Oncological Rehabilitation, Austria

Emanuele Zucca, MD, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Publishing editor: Anna Fenzl, PhD

Lecture Board for this issue: Nitin Jain, MD; Nadine Kutsch, MD; Kiyomi Mashima, MD, PhD; William F. Mawalla, MD; Constantine Tam, MD; Rachel Thijssen, PhD; Adrian Wiestner, MD, PhD.

Medical Writer for this issue: Judith Moser, MD

BeiGene Supported by BeiGene in the form of an unrestricted grant

memo © Springer-Verlag GmbH Austria, part of Springer Nature Vol. 16 ∙ Suppl 10/2023 S163